German SciRhom GmbH and New York’s Hospital for Special Surgery (HSS) have collaborated on proof-of-concept studies leading to the announcement of the first-in-class antibodies against iRhom2, a key modulator of several major pro-inflammatory signaling pathways such...
Pin It on Pinterest
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site you consent to our use of cookies.Ok
